Videos

A key opinion leader discusses the use of oral agents for the preventive treatment of migraine.

Dr Christopher Gottschalk shares how the clinical trial data for CGRP monoclonal antibodies affect patient selection for preventive migraine treatment.

The clinical associate professor of neurology at the University of Michigan spoke on the importance of sleep medicine education for trainees, as well as areas that could be improved. [WATCH TIME: 3 minutes]

The Distinguished Professor of Neuromuscular Disease at University of North Carolina School of Medicine offered his insight into the newly approved Argenx agent, marketed as Vyvgart. [WATCH TIME: 3 minutes]

The clinical associate professor of neurology at the University of Michigan outlined a recent study that assessed the effectiveness of an educational sleep medicine “boot camp.” [WATCH TIME: 2 minutes]

The research assistant professor at the Buffalo Neuroimaging Analysis Center detailed the improvements the current batteries for detecting cognitive impairment in MS need. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending December 25, 2021.

A panel of neurologists review clinical trial data on several CGRP monoclonal antibodies for migraine preventive treatment.

Expert neurologists discuss the use of CGRP monoclonal antibodies to prevent migraines.

Jeffrey L. Cummings, MD, ScD, discusses the biomarker assessments used to test for amyloid beta that can confirm disease pathology for Alzheimer’s disease.

Jeffrey L. Cummings, MD, ScD, explains the pathophysiology and common screening tools used to evaluate Alzheimer’s disease.

The chief medical officer of Cognetivity Neurosciences outlined the benefits a new integrated assessment has for clinicians and patients with dementias and multiple sclerosis. [WATCH TIME: 4 minutes]

Following previous discussions about novel oral therapies available as treatment for relapsing-remitting multiple sclerosis, a small panel of neurologists comment on factors that affect which agent they select.

Characteristics that make the purine antimetabolite, cladribine, a unique treatment option for relapsing-remitting multiple sclerosis.

The research assistant professor at the Buffalo Neuroimaging Analysis Center discussed a recently awarded grant to determine which brain structures are responsible for cognitive decline in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

The director of the Joseph Epstein Center for Emergency Medicine Research discussed why guidelines developed by international bodies would provide crucial direction for emergency departments in how they treat presenting headache. [WATCH TIME: 3 minutes]

Although the new integrated cognitive assessment can be completed remotely, the chief medical officer of Cognetivity outlined its potential for use in the clinical setting.

Shared insight on how daytime functioning has become part of the insomnia treatment paradigm.

Expert perspectives on how patients may present differently with acute vs chronic insomnia.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, provided context on improving our use of current antiseizure medications as the top priority for patients with epilepsy. [WATCH TIME: 2 minutes]

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

The chief medical officer of Cognetivity outlined a new integrated cognitive assessment that takes only 5 minutes to complete on an iPad. [WATCH TIME: 6 minutes]

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, provides an overview of the use of onabotulinumtoxinA as a preventive migraine treatment.

A thought leader explains how she involves the patient when selecting novel agents to add to a preventive migraine treatment plan.

The staff neurologist at the Cleveland Clinic Mellen Center for Multiple Sclerosis outlined key findings from her talk at a recent Institutional Perspectives in Neurology: Multiple Sclerosis event. [WATCH TIME: 3 minutes]

The director of the Joseph Epstein Center for Emergency Medicine Research discussed the complexities of diagnosing migraine in the emergency department and whether institutions should reevaluate their internal processes to do so. [WATCH TIME: 3 minutes]

The director of the epilepsy center at Cleveland Clinic Neurological Institute spoke on one of the studies he coauthored that were presented at AES 2021. [WATCH TIME: 4 minutes]

The advantages of using the pyrimidine synthesis inhibitor teriflunomide to treat relapsing-remitting multiple sclerosis.

Considerations that affect which S1P receptor modulator may be used to treat relapsing-remitting multiple sclerosis, and how to best utilize them during COVID-19.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the need for specificity and artificial intelligence for patients with epilepsy. [WATCH TIME: 4 minutes]